Date: 2012-05-15
Type of information: Commercialisation agreement
Compound: Pamorelin® LA (triptorelin in the form of pamoate salt), Salvacyl®
Company: Debiopharm (Switzerland) Vifor Pharma (Switzerland)
Therapeutic area: Cancer - Oncology - Gynecology - Women's health
Type agreement: distribution
commercialisation
Action mechanism: Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH).
Disease: prostate cancer, endometriosis
Details: Debiopharm and Vifor Pharma have signed an exclusive agreement for the distribution and commercialization of Pamorelin® LA. This agreement covers the distribution and commercialization in Switzerland of the 1-, 3- and 6-month formulations of Pamorelin® LA and of the 3-month formulation of Salvacyl®. It came into effect on 9 May 2012. Pamorelin® LA, which contains the active substance triptorelin in the form of pamoate salt, is indicated in the treatment of advanced hormone-dependent prostate cancer, endometriosis and female infertility. Salvacyl® is indicated in the treatment of severe sexual deviation in men.
The 1- and 3-month formulations of Pamorelin® LA are available immediately, while the introduction of the 6-month formulation of Pamorelin® LA and Salvacyl® will be communicated by Vifor Pharma at a later date.
Developed by Debiopharm, the products Pamorelin® LA and Salvacyl® are manufactured by Debio R.P. in Martigny, Debiopharm's site for applied research, controlled release formulation development and production.
Financial terms:
Latest news:
